Table 3. Outcomes after alloSCT... | American Society of Hematology

Table 3.

Outcomes after alloSCT according to the ELN 2017 risk stratification

	OS after alloSCT, % (SE)	EFS after alloSCT, % (SE)	CIR after alloSCT, % (SE)	Cumulative incidence of death without relapse after alloSCT, % (SE)
All patients	2 y, 58.2 (2.6)	2y, 52.5 (2.7)	2y, 26.7 (2.3)	2y, 20.8 (2.1)
ELN 2017 favorable	2 y, 70.5 (5.4)*	2 y, 66.6 (5.6)*	2 y, 17 (4.6)^†	2 y, 16.4 (4.2)NS
ELN 2017 intermediate	2 y, 67.4 (5.7)	2 y, 58.5 (6.4)	2 y, 29 (6.1)	2 y, 12.5 (4)
ELN 2017 adverse	2 y, 46.9 (4.5)	2 y, 40.8 (4.4)	2 y, 36.1 (4.2)	2 y, 23.1 (3.6)

	OS after alloSCT, % (SE)	EFS after alloSCT, % (SE)	CIR after alloSCT, % (SE)	Cumulative incidence of death without relapse after alloSCT, % (SE)
All patients	2 y, 58.2 (2.6)	2y, 52.5 (2.7)	2y, 26.7 (2.3)	2y, 20.8 (2.1)
ELN 2017 favorable	2 y, 70.5 (5.4)*	2 y, 66.6 (5.6)*	2 y, 17 (4.6)^†	2 y, 16.4 (4.2)NS
ELN 2017 intermediate	2 y, 67.4 (5.7)	2 y, 58.5 (6.4)	2 y, 29 (6.1)	2 y, 12.5 (4)
ELN 2017 adverse	2 y, 46.9 (4.5)	2 y, 40.8 (4.4)	2 y, 36.1 (4.2)	2 y, 23.1 (3.6)

NS, not significant; SE, standard error.

P < .001.

P < .01.